Bystander cells present in human lung and colorectal tumors could indicate how well a patient will respond to immunotherapy, an A*STAR-led study finds.
Jul 16, 2018
0
10
Chikungunya virus (CHIKV) infection may reduce the severity of malaria, according to a discovery by A*STAR scientists, which could lead to the development of new malaria treatments.
Jun 25, 2018
0
3
An effective method of screening patients for closed-angle glaucoma has been developed by A*STAR researchers.
Jun 25, 2018
0
0
The current understanding of limb and lung development in humans does not capture the full picture of the process, according to research published in Nature last week. This paper describes the importance of novel genes for ...
May 24, 2018
0
3
A scalable method of generating universal 'off-the-shelf' natural killer (NK) cells for cancer immunotherapies has been devised by A*STAR researchers. Their technique could ensure that future NK cell-based cancer treatments ...
May 16, 2018
0
16
A pioneering technique developed by A*STAR researchers can identify and profile specific groups of immune cells that target cancer cells in individual patients. This approach could open the door to personalized cancer treatments.
May 2, 2018
0
1
An innovative approach to protein engineering could help make antibody-based drug therapies less toxic and more effective.
May 2, 2018
0
1
In a pioneering study, scientists at A*STAR's Genome Institute of Singapore (GIS) have developed new machine learning computer models, a type of artificial intelligence (AI), to accurately pinpoint cancer mutations. They ...
Apr 19, 2018
1
109
A single letter DNA mutation is a big determinant of whether patients with advanced oral cancer respond to treatments. Researchers from the National Cancer Centre Singapore (NCCS) and A*STAR who uncovered the mechanisms behind ...
Mar 23, 2018
0
3
RNA-based therapeutics that prevent a key metabolic enzyme from being expressed in tumor-initiating cells (TIC) hold promise for the treatment of lung cancer, an A*STAR team has shown.
Mar 23, 2018
0
10
